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Background: MicroRNAs expression has been extensively studied in hepatocellular carcinoma but little is known
regarding the relationship, if any, with inflammation, production of reactive oxygen species (ROS), host’s repair
mechanisms and cell immortalization. This study aimed at assessing the extent of oxidative DNA damage (8-
hydroxydeoxyguanosine - 8-OHdG) in different phases of the carcinogenetic process, in relation to DNA repair gene
polymorphism, telomeric dysfunction and to the expression of several microRNAs, non-coding genes involved in
post-transcriptional regulation, cell proliferation, differentiation and death.
Methods: Tissue samples obtained either at surgery, [neoplastic (HCC) and adjacent non-cancerous cirrhotic tissues
(NCCT)] at percutaneous or laparoscopic biopsy (patients with HCV or HBV-related hepatitis or patients undergoing
cholecystectomy) were analysed for 8-OHdG (HPLC-ED), OGG1 (a DNA repair gene) polymorphism (PCR-RFLP),
telomerase activity, telomere length (T/S, by RT-PCR), Taqman microRNA assay and Bad/Bax mRNA (RT-PCR). Fifty-eight
samples from 29 HCC patients (obtained in both neoplastic and peritumoral tissues), 22 from chronic hepatitis (CH)
and 10 controls (cholecystectomy patients - CON) were examined.
Results: Eight-OHdG levels were significantly higher in HCC and NCCT than in CH and CON (p=0.001). Telomerase
activity was significantly higher in HCC than in the remaining subgroups (p=0.002); conversely T/S was significantly
lower in HCC (p=0.05). MiR-199a-b, -195, -122, -92a and −145 were down-regulated in the majority of HCCs while miR-
222 was up-regulated. A positive correlation was observed among 8-OHdG levels, disease stage, telomerase activity,
OGG1 polymorphisms and ALT/GGT levels. In HCC, miR-92 expression correlated positively with telomerase activity, 8-
OHdG levels and Bad/Bax mRNA.
Conclusions: The above findings confirm the accumulation, in the progression of chronic liver damage to HCC, of a
ROS-mediated oxidative DNA damage, and suggest that this correlates with induction of telomerase activity and, as a
novel finding, with over-expression of miR-92, a microRNA that plays a role in both the apoptotic process and in
cellular proliferation pathways.
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Sound data suggest that reactive oxygen species (ROS)
play a pathogenic role in carcinogenesis by inducing oxi-
dative DNA damage, modulating gene expression, altering
different signaling pathways and leading to a deregulation
of cell proliferation and apoptosis [1-4]. ROS-induced
DNA oxidation leads to a multitude of modifications to
DNA bases, with 8-hydroxydeoxyguanosine (8-OHdG)
representing the most frequent one. Eight-OHdG, a guan-
ine adduct used as an index of DNA oxidative damage,
induces a point mutation in the daughter DNA strands,
accumulates in cell DNA and causes mispairing, thus
demonstrating its mutagenic and potentially carcinogenic
role [5]. During virus-related liver disease, both in humans
and experimental models, an increased production of ROS
has been documented, with a strong link between HCV
core protein or HBV X protein and an oxidative “burst”
[6,7]. These early events are followed in the progression of
the disease by a build-up of genomic oxidative damage in
patients with chronic hepatitis and cirrhosis, as documen-
ted in our own and other authors’ findings [8-11].
Several DNA repair mechanisms have specifically
evolved and oxidized bases are repaired by a highly con-
served base excision repair pathway, initiated by excision
of the damaged base by glycosylases and by DNA strand
cleavage. Four major DNA glycosylase, OGG1, NTH1,
NEIL1 and NEIL2 have been characterized in human
cells [12]. The OGG1 gene encodes for a DNA glycosi-
lase/AP lyase which removes the oxidised DNA bases. It
is located on chromosome 3p26.2 and a CG polymorph-
ism at position 1245 exon 7 of the gene [with substitu-
tion of cysteine for serine at codon 326 (Ser326Cys)] has
been described, that is associated with a significantly
lower DNA repair activity by the coded enzyme [13].
Amongst the many potential targets of oxidative damage
are microRNAs (miRNAs) [14]. miRNAs are a family of
non-coding genes, involved in post-transcriptional gene
regulation, in cell proliferation, differentiation, cell death
and carcinogenesis, that have been reported to play an im-
portant role in chronic liver damage progression and
hepatocellular carcinoma (HCC) development [15].
A list of miRNAs differentially expressed in HCC com-
pared to non-cancerous liver has been indeed described
[16], among which the liver specific miRNA, miR-122,
often under-expressed in hepatic tumours, which also
interacts with the 5′ noncoding region of HCV genome
[17,18]. Several others miRNAs are involved in cell cycle
control; some of these, such as the miR-17-92 cluster,
miR-21, miR-221/miR-222, miR-224 and miR-146a, are
up-regulated in HCC, others, including miR-125b, miR-
1, miR-195, miR-223, miR-101 and miR-145, down-
regulated [18,19]. These miRNAs may inhibit apoptosis,
facilitate invasion and metastasis, act as either tumor
suppressors or oncogenes [16] and have been associatedwith cell differentiation, self-renewal and tumor initi-
ation in vivo, as in the case of the miR-181 family, over-
expressed in hepatic cancer stem cells [20].
miRNAs, as oxidative DNA damage, are also involved in
the regulation of telomerase activity [21], which is up-
regulated in mutated cells activity [22]. Telomeric DNA
indeed is particularly rich in guanine residues and, under
ROS attack, is highly prone to 8-OHdG formation [23].
The resulting telomere shortening, with chromosome in-
stability, involves the first phases of carcinogenesis while
tumor progression is linked to a reactivation of telomerase
activity, with telomere elongation and cell immortalization
[24,25].
On these premises, the aims of this study were to:
– confirm the accumulation of oxidative DNA damage
in the different phases of the liver carcinogenetic
process and ascertain whether OGG1 gene
polymorphisms modulate the extent of damage;
– evaluate, in the same model, telomerase activity,
telomere length and any effect of 8-OHdG and of
OGG1 gene polymorphism on both;
– investigate the expression of a panel of miRNAs
with possible direct or indirect interference on
cellular oncogenes and tumor suppressors justifying
their involvement in the pathogenesis of HCC, in
relation to oxidative DNA damage, telomerase
activity and factors involving in apoptotic
mechanisms, including Bad and Bax [26].
Methods
This study was carried out in tissue samples of patients
with either HCC undergoing surgical resection or
chronic virus-related liver damage undergoing US-
guided liver biopsy and, as control group, in patients
undergoing cholecystectomy.
Sixty-one patients (corresponding to 90 samples)
entered the study;
– twenty-nine patients with HCC, 20 males and 9
females, mean age 62 (±13), entered the study and
during the surgical resection both a neoplastic
sample (HCC) and a sample from the non-
cancerous cirrhotic tissue surrounding the resected
nodules (NCCT) were obtained, for a total of 58
samples. Etiology of the disease was as follows: HBV
or HCV-related 15 patients (52%), alcohol 5 patients
(17%), other factors or cryptogenic 9 patients (31%);
– twenty-two patients with HCV or HBV-related
chronic liver damage (CH) (20 HCV, 2 HBV) 12
males, 10 females, mean age 53 (±8), also entered
the study. In this case, part of the liver biopsy
samples (obtained by 16/17 Gauges Menghini
modified needles under US guidance) was devoted
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than 2 cm) was used for the routine histological
examination;
– finally, ten patients undergoing cholecystectomy
were submitted, during laparoscopy, to liver biopsy
with the same modalities as above (6 females and 4
males, mean age 56 (±7) (CON).
In each patient anti-HCV antibodies were looked for
using a second-generation ELISA and all positive sera
were confirmed by RIBA II assay. In all patients, anti-
HCV sera positivity was confirmed by positive HCV-
RNA levels determination using the Amplicor HCV test
(Amplicor PCR Diagnostic, Hoffman-La Roche, Basel
Switzerland). A standardized genotyping assay (Inno-
Lipa HCV III, Innogenetics, Gent, Belgium) was used.
The HBV group consisted of individuals who were
HBsAg, anti-HBe, and HBV-DNA positive at PCR. HBV
serum markers were tested by radioimmunoassay (RIA)
(Abbott, Chicago, IL, USA), while HBV-DNA levels were
tested using a commercially-available fluid phase
hybridization assay (Abbott, Chicago, IL, USA).
After obtaining informed consent, the patients pro-
vided full information relative to their drinking and
smoking habits and completed a food frequency ques-
tionnaire with particular attention to their intake of vita-
mins. Patients with concurrent diseases or those taking
medications capable of interfering with free radical pro-
duction, such as non-steroidal anti-inflammatory drugs
(NSAIDs) or anti-oxidants (vitamin C), were excluded
from the study.
The study that was approved by the Ethic Committee
of Padua Hospital.
Genomic DNA extraction from biopsy and surgical liver
sample
Genomic DNA extraction from surgical liver samples
and biopsies was made on portions of tissues immedi-
ately snap-frozen in liquid nitrogen and stored at - 80°C
until use. For DNA extraction we used a Wizard Gen-
omic DNA Purification Kit (Promega Italia, Milano,
Italy) according to the protocol provided. The liver tis-
sues (approximately 10 mg) were homogenized with pes-
tle in a solution of EDTA 0.5 M pH 8, Nuclei Lysis
Solution and Proteinase K (20mg/ml).
Quantification of 8-OHdG adduct
This assay was performed with a portion of the liver ma-
terial (both surgical and biotic samples), and consisted of 3
steps: (i) genomic DNA extraction using a Wizard Gen-
omic DNA Purification Kit (Promega Italia, Milano, Italy);
(ii) nuclease P1 and alkaline phosphatase hydrolysis of
DNA; (iii) 8-OHdG determination using HPLC-ED, which
is a highly sensitive method with a detection limit of ~2adducts per 105 deoxyguanosine (dG). Following nuclease
P1 and alkaline phosphatase hydrolysis, samples were fil-
tered through 0.22-mm nylon filters (Scientific Resources,
Alfatech, Genova, Italy), and 20 μL DNA per sample was
injected in the HPLC (Alliance 2695, Waters, Milano).
Eight-OHdG and normal deoxynucleosides were separated
in a 3-mm Supelcosil LC-18-DB analytical column (7.5 cm
× 4.6 mm, Supelco, Bellefonte, PA) equipped with a 5-mm
SupelguardTM LC-18-DB guard column cartridge.
The solvent system consisted of an isocratic mixture
of 90% of 50 mM potassium phosphate, pH 5.5, and 10%
methanol at a 1 ml/min flow rate.
The 8-OHdG was detected using an electrochemical
detector (ESA Coulochem II 5200 A, Bedford, MA)
equipped with a high-sensitivity analytical cell, model
5011, with the oxidation potentials of electrodes 1 and 2
adjusted to 0.15 and 0.35 V, respectively. The levels of 8-
OHdG were referred to the amount of dG detected in the
same sample by UV absorbency at 254 nm. The amount
of DNA was determined from a calibration curve vs.
known amounts of calf thymus DNA. The 8-OHdG levels
were expressed as the number of 8-OHdG adducts per
105 dG. An 8-OHdG standard (Sigma-Aldrich, St. Louis,
MO, USA), prepared immediately before the assay, was
injected before any set of samples. The coefficient of vari-
ation was <10%; the amount of DNA required for the
assay was 100 μg. Samples with lower amounts of DNA
were rejected, since the risk of methodological error is
only acceptable above this cut-off.OGG1 gene: PCR and Restriction Fragment Length
Polymorphism (RFLP) Analyses
Cellular DNA isolated from tissue samples was analyzed
by PCR to study the C:G transversion at nucleotide 1245
of the OGG1 gene. An aliquot of 100 ng of genomic DNA
was added to a 25 μl PCR mixture and PCR was per-
formed using the primers described by Kohno et al. [27],
5′-AGGGGAAGGTGCTTGGGGAA--3′ as the forward
primer and 5′ –ACTGTCACTAGTCTCACCAG - 3′as
the reverse primer.
The thermoprofile consisted of 30 cycles of denatur-
ation at 94°C for 15 sec, annealing at 58°C for 15 sec
and extension at 72°C for 40 sec, preceded by an initial
denaturation step at 94°C for 2 min followed by a ter-
minal extension at 72°C for 5 min. The 1245 C:G trans-
version was identified using PCR-RFLP. Briefly, 10 μl of
the 200-bp PCR product was digested with Fnu4HI. The
presence of a C:G transversion creates a Fnu4HI recog-
nition site, which leads to digestion of the 200-bp PCR
product into 2 fragments of 100 bp. Heterozygous sub-
jects exhibit 2 fragments (200 and 100 bp), and a homo-
zygous C:G transversion results in the appearance of a
single fragment of 100 bp. Fnu4HI digests of PCR
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on 3% agarose gels after ethidium bromide staining.
Protein extraction from surgical and bioptic liver sample
Liver samples were lysed in 200 μl of CHAPS buffer
containing Protease Inhibitor Cocktail (Sigma-Aldrich,
St. Louis, MO, USA) and incubated at 4°C for 30 min.
The lysate was centrifuged at 14000 rpm for 45 min at
4°C and the supernatant was collected −80°C. The pro-
tein concentration was measured using RCDC Protein
Assay (Bio-Rad, Milano, Italy).
Real Time Quantitative–Telomeric Repeat Amplification
Protocol (RTQ-TRAP) for telomerase activity
Each hepatic sample was assayed for telomerase activity,
starting from protein extracts of the liver tissue stored at
−80°C, by an ABI 7900 Sequence Detection System (Ap-
plied Biosystems, Foster City, CA, USA). The total volume
of the reaction mixture was 25 μl in SYBR Green PCR
Master Mix (Applied Biosystems, Foster City, CA, USA)
contained DNA polymerase Ampli-Taq Gold, dNTPs and
dUTP, 1X SYBR Green buffer, 0.2 μg of T4 gene protein,
primers TS (5′-AATCCGTCGAGCAGAGTT-3′) 0.6 μM,
ACX [5′-GCGCGG(CTTACC)3CTAACC-3′] 0.4 μM and
1 μg/μl of protein extract. The PCR was performed in a
96-well micro titer plate and the reaction mixture was first
incubated at 25°C for 20 min to allow the telomerase in
the protein extract to elongate the TS primer by adding
TTAGGG repeat sequences.
PCR then started at 95°C for 10 min, followed by a 40-
cycle amplification at 95°C 20 s and 60°C for 30 s. All
samples were assayed in triplicate to test the reproduci-
bility of the RTQ-TRAP assay, and in each assay also a
protein extract of a cell line (PLC/PRF/5) as positive
control and water as negative control were evaluated.
Following amplification, a dissociation curve was per-
formed in order to confirm the specificity of the reac-
tion. Fluorescence signals and dissociation curves were
collected and analyzed by ABI 7900 SDS 2.3 software so
telomerase activity in cells line and samples was calcu-
lated based on the threshold cycle (Ct).
Telomerase activity in cells line and samples was
extrapolated using a standard curve prepared with serial
dilutions of Telomerase Control Oligo Standard (amol/
μl) containing telomeric repeats (TAAGGG). Telomerase
activity was expressed as percentage compared to that in
PLC/PRF/5 cells.
Telomere length analysis by quantitative PCR
Genomic DNA extracted was used also to measure telo-
mere length by using method developed by Cawthon
[28]. Two 96-well plates were prepared for each experi-
ment, one of which containing telomere primers(Tel-1:5′-GGTTTTTGAGGGTGAGGGTGAGGGTGA
GGGTGAGGGT-3′, Tel-2: 5′- TCCCGACTATCCCTAT
CCCTATCCCTATCCCTATCCCTA-3′) and the other
for 36B4, encoding acidic ribosomal phosphoprotein
P0 used as the single copy gene (36B4u: 5′-
CAGCAAGTGGGAAGGTGTAATCC-3′, 36b4d: 5′-
CCCATTCTATCATCAACGGGTACAA-3′).
Each 25 μl PCR reaction included 40 ng of DNA,
SYBR Green Master Mix (Applied Biosystems, Foster
City, CA, USA) and primers at final concentrations 270
nM Tel-1 and 900 nM Tel-2 or 300 nM 36B4u and 500
nM 36B4d, respectively.
PCR amplification was performed in a ABI PRISM 7900
(Applied Biosystems, Foster City, CA, USA). In each plate,
a standard curve was produced ranging from 4 to 80 ng of
human reference DNA (Applied Biosystems, Foster City,
CA, USA). The thermal cycling profile for the telomere
amplification was 95°C for 10 min, followed by 30 cycles
of 95°C for 5 s, 56°C for 10 s and 72°C for 60 s or 30 cycles
of 95°C for 5 s, 58°C for 10 s and 72°C for 40 s. Following
amplification, a dissociation curve was performed in order
to confirm the specificity of the reaction.
All samples were assayed in triplicate to test the repro-
ducibility and in each assay was evaluated a negative
control. Fluorescence signals and dissociation curves
were analyzed by ABI 7900 SDS 2.3 software. Telo-
meres/single copy gene (T/S) ratio for each sample were
obtained by dividing the mean amount of telomeres by
the mean amount of 36B4 gene.
miRNAs expression: Taqman microRNA assay
We started from 0.1g of frozen tissue for each sample
and RNA extraction was performed through mirVana
miRNA isolation kit (Ambion, Austin, TX, USA), a
method which combines phenol-chloroform and fiber-
glass columns to obtain total RNA enriched in miRNAs.
RNA was eluted in RNAse-free water and stored at −80°
C; concentration and quality were checked with Nano-
drop (Thermo Scientific, Canada, USA). The expression
of a selected panel of miRNAs was then evaluated by
mean of RT-PCR, using TaqMan microRNA assay (Ap-
plied Biosystems, Foster City, CA, USA). 10ng of RNA
were reverse translated for each sample using looped
primers specific for each miRNA and the obtained
cDNA was assayed with real-time PCR with miRNA spe-
cific primers and TaqManW probes. Data obtained for
each miRNA were normalized versus a control RNA
(RNU6B) and the relative expression for coupled tumour
and normal samples was expressed by ΔΔCT method.
Reverse transcription for Bad/Bax mRNA determination
For the synthesis of complementary DNA (cDNA), 2 μg
of RNA were reverse transcribed in a final volume of 40
μl in the presence of 1X PCR buffer, 1 mM each of
Figure 1 8-OHdG levels in liver tissues in different stages of the
disease progression. 8-OHdG mean levels were significantly higher
in NCCT than in other groups (CON, CH, HCC), p = 0.01 Anova one-
way. CON Controls (10), CH HCV and HBV Positive Chronic Hepatites
Tissues (22), NCCT Non-Cancerous Cirrhotic Tissues (29), HCC
Neoplastic Tissues (29).
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tor, 2.5 μM random hexamers, and 2.5 U of murine
leukemia virus (Perkin Elmer, Foster City, CA, USA).
The reverse transcription reaction was completed at 25°
C for 10 min, 42°C for 15 min and 99°C for 5 min, in a
Perkin Elmer GeneAmp PCR System 2400. The cDNA
was stored at −20°C.
Quantitative absolute real-time PCR
Real-time PCR was conducted in an ABI 7900 Sequence
Detection System (Applied Biosystems, Foster City, CA,
USA) using SYBR Green I. The reaction was obtained on
96-well plates, in a 25 μL final volume containing 1X Taq-
Man buffer, 5.5 mmol of MgCl2, 200 μmol of nucleotides
with dUTP, 0.25 U of AmpliTaq Gold Polymerase (SYBR
Green Master Mix), 300 nM of each primer and 200 ng of
cDNA template. Nucleotide sequences for the sense and
antisense primers used for real-time PCR were: 5′-CTTT-
TGCTTCAGGGTTTCATCC-3′, 5′-TTGAGACACTCG
CTCAGCTTCT-3′ for Bax [ENST00000356483], and the
length of this amplicon was 119 bp; 5′- TCTATGCAAG
TTTTGCCCTTTGTA-3′, 5′-GCCAGCCTGAATGAAA
TGA- 3′ for BI-1 [ENST00000267115], and the length of
this amplicon was 84 bp; 5′-CCTGGCACCCAGCACAA-
3′, 5′-GCCGATCCACACGGAGTACT for β-actin
[ENST00000158302], and the length of this amplicon was
70 bp. After one 2-min step at 50°C and a second step at
95°C for 10 min, samples underwent 45 cycles of 45 s at
94°C and then: 45 s at 60°C for Bax and β-actin; 45 s at
65°C for Bad. A final extension step was performed at 60°
C for 10 min.
Statistics
The data obtained were initially examined for their dis-
tribution with the Kolmogorov-Smirnov test and then
compared by either Anova One Way or Kruskal Wallis
test. Correlation analysis were performed by either linear
correlation analysis or Spearman Rank correlation ana-
lysis, as appropriate. The chi square test was used when
indicated. A p value < 0.05 was considered as signifi-
cant. The StatsDirect and PASW Statistics programs
were used.
The power analysis for the data evaluated with un-
paired two sample Student t tests showed the all the
comparison with controls, with an 80% power and a 5%




Oxidative DNA damage, as measured by the quantifica-
tion of liver tissue 8-OHdG levels, was significantly
higher in NCCT than in other groups (176±53 vs 142
±33 HCC vs 76±7 CH vs 12±4 CON 8-OHdG/105 dG,p=0.01, Anova one-way), also if no significant difference
emerged between HCC and NCCT (Figure 1). With the
limitations given by the relatively small sample size, no
difference was observed between virus-related and non
virus-related HCC in both HCC and NCCT tissues (data
not shown).
OGG1 gene polymorphism analysis
With respect to OGG1 gene polymorphism, heterozygous
CG or homozygous GG polymorphisms were detected
more frequently in CON and CH patients than in HCC,
even not significantly so (50% vs 54% vs 26%, p=n.s).
Telomerase activity
As expected, an increased telomerase activity was
detected in HCC (median 10.9 amol/μl, 0.6-77.9, 95%
CI), versus all other patients groups (CON, CH and
NCCT) (2.6 amol/μl, 1.7-8.6 95% CI; 6 amol/μl, 5.4-19
95% CI; 2.2 amol/μl, 0.1-22,1 95% CI respectively,
p=0.002, Kruskal-Wallis) (Figure 2). Telomerase activity
was higher than the upper 95% CI of CON in 34% of
CH, 22% of NCCT and 53% of HCC.
No correlation was found between telomerase activity
and OGG1 polymorphisms.
Telomeres’ lenght
Conversely, telomere length significantly decreased from
CON and CH to NCCT and HCC (0.5±0.09 vs 0.5±0.06 vs
0.3±0.09 vs 0.2±0.03, p=0.05 Anova one-way) (Figure 3).
miRNAs expression analysis and correlations
The study of the levels of expression of the panel of
miRNAs assayed with RT-PCR in coupled tumor and
Figure 2 Telomerase activity detected in liver tissues in
different stages of the disease. Mean/median levels of telomerase
activity were higher in HCC patients’ group than other groups (p =
0.002 Kruskal-Wallis). CON controls (10), CH HCV- and HBV- Related
Chronic Hepatitis Tissues (22), NCCT Non-Cancerous Cirrhotic Tissues
(29), HCC Neoplastic Tissues (29).
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following results:
– seven miRNAs showed a relevant deregulation in
HCC tissues with respect to NCCT: miR-222
showed a high rate of over-expression (two-fold
increase in 45% of the patients, significantly more
frequently hyperexpressed than any other miRNAs,
p=0.0065), while the levels of miR-92a, miR-122,
miR-195, miR-199a, miR-199b and miR-145 showed
a lower expression in HCC tissues (two-fold
decrease ranging from 41% of patients for miR-92aFigure 3 Telomeres’ length detected in liver tissues in different
stages of the disease. Mean levels showed a significant reduction
in the progression of disease to HCC (p = 0.05 Anova one-way). CON
Controls (10), CH HCV and HBV Positive Chronic Hepatites Tissues
(22), NCCT Non-Cancerous Cirrhotic Tissues (29), HCC Neoplastic
Tissues (29).up to 69% of patients for mir-199a). MiR-18a
expression was not different in the two tissues
(Figure 4).
– in the multiple correlation analysis, 8-OHdG levels
were found to be significantly correlated with:
histological diagnosis (p=0.01), NCCT telomerase
activity (p=0.0001), HCC OGG1 polymorphism
(p=0.05), ALT and GGT levels (p=0.01 and p=0.03,
respectively). MiR-92a expression was significantly
correlated with telomerase activity (p=0.004) and 8-
OHdG levels (p=0.05) in HCC tissues and Bax
mRNA both in NCCT and HCC tissues (p=0.05).
Besides, 8-OHdG levels correlated with Bad mRNA
in HCC tissues (p=0.05) (Table 1).
Discussion
This study was aimed at defining the interrelationships
among oxidative damage, telomerase activity, telomeric
dysfunction and miRNAs expression in the progression
of chronic liver damage and HCC development.
Our data confirm what ourselves and other authors
already published on the relevance of oxidative DNA
damage in the progression from chronic liver damage to
HCC in virus-related liver damage, confirming the pro-
gressive accumulation of DNA damage that reaches a
maximum in both the neoplastic and in the adjacent
non-cancerous cirrhotic tissues. This last finding clearly
indicates the presence of a “field defect” that most prob-
ably contributes to the multifocal and relapsing nature
of HCC in cirrhosis [29].
Our results demonstrated the lack of a specific signifi-
cant association of OGG1 polymorphisms with HCC de-
velopment. CG and/or GG polymorphisms, which are
reportedly linked to a lower repair capacity in other can-
cers [30,31], as also confirmed in our own experience
[32], were less frequently detected in cirrhosis and HCC
samples. There are several other repair enzymes poten-
tially involved in repairing DNA oxidative damage [33]
and the lack of association with OGG1 polymorphisms
probably indicates that, in the liver, other repair
mechanisms are more relevant than OGG1. On the
other hand, a significant correlation was documented
between OGG1 polymorphisms and 8-OHdG levels,
overall, thus confirming that, when the polymorphism
associated with lower repair capacity is present, oxida-
tive DNA damage accumulates, irrespective of the phase
of the disease and of the activity of other repair systems.
Our findings also confirm that an increased telomerase
activity is a feature of HCC, in agreement with the data
reporting that a high percentage of HCC cases show an
increased telomerase activity [34-36]. Using the data
obtained in the control population, telomerase activity
was increased in over 50% of the cases. Despite this
increased activity, telomeres were significantly shorter in
Figure 4 Results of the miRNAs expression in the samples of liver tissues. Each value represents the ratio of expression HCC/NCCT
calculated using the ΔΔCt method (HCC/NCCT= 2- ΔΔCt ) on the average of the repetitions of each sample. The inclusion in the expression
categories has the ratio 2 (or 0.5) as threshold with a margin of 5% confidence. MiR-222 was more frequently hyperexpressed than any other
miRNAs (p=0.0065). NCCT Non-Cancerous Cirrhotic Tissues (29), HCC Neoplastic Tissues (29).
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reported that HCC tissues are frequently characterized by
an increased oxidative damage which contributes to the
acceleration of telomere shortening and the activation of
telomerase in cancer cells. Telomeres act as protective
caps at the ends of chromosomes and telomere shortening
promotes chromosomal instability. It is not therefore sur-
prising that telomere shortening occurs during the course
of chronic liver disease and in hepatocarcinogenesis.Table 1 Multiple and linear correlation analysis
8-OHdG
Histological diagnosis p = 0.01
NCCT telomerase activity p = 0.0001
HCC OGG1 polymorphism p = 0.05
ALT p = 0.01
GGT p = 0.03
miR-92
HCC 8-OHdG p = 0.05
HCC telomerase activity p = 0.004
HCC Bax mRNA p = 0.05
NCCT Bax mRNA p = 0.05
8-OHdG
HCC Bad mRNA p = 0.05
NCCT Non-Cancerous Cirrhotic Tissues (29)
HCC Neoplastic Tissues (29)The data we obtained with respect to miRNAs in the
study are largely in agreement with well established lit-
erature reports on miRNAs expression in HCC. In par-
ticular, miR-222 was found overexpressed in the
neoplastic tissue, consistently with other findings on
HCC, pancreatic and gastric cancer [18]. Also the under
expression we observed with respect to miR-199a, miR-
199b, miR-195 and miR-122 in tumour samples supports
what reported by many other groups in HCC [37,38] as
well as in other cancers [39-41]. MiR-92a, part of miR-
17-92 cluster, was instead found under-expressed in
nearly one half of the tumour samples investigated [42].
This result is in contrast with what reported in several
publications regarding an overexpression of the entire
miR-17-92 cluster in most cancers. In many cases how-
ever the individual behaviour of miR-92a was not well
defined in these papers [43,44]. On the other hand, our
data are in agreement with a number of studies which
reported a decrease in miR-92a expression in association
with a deletion in chromosome 13q that encodes for the
miR-17-92 cluster [45,46], a relatively frequent finding in
cancer samples.
The miR-17-92 cluster indeed encodes seven miRNAs,
which are tightly grouped within an 800 base-pair region
of chromosome 13q and apparently play a role in both the
apoptotic process and in cellular proliferation pathways.
In fact, some members of the E2F family of transcription
factors, which are critical regulators of cell cycle and
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progression from G1 into S phase), were among the first
experimentally verified target of the miR-17-92 cluster
[47]. Nevertheless, the way by which miR-92a deregulation
can influence carcinogenesis in virus-related liver still
needs to be elucidated and some hypotheses have been
formulated to explain the mechanisms behind this finding:
a. the down regulation of miR-17-92 family may be
advantageous for cancer development: as previously
mentioned, loss-of-heterozygosis at miR-17-92 locus
(13q31.3) has been observed in multiple tumour
types (including HCC) [45]; moreover, the down
regulation of another member of the cluster, miR-17,
has been reported to contribute to breast cancer
development through over expression of its target,
the oncogene AIB1 [48].
b. many of the miRNAs that have been reported to be
up regulated in a variety of cancer cells, as miR-17-
92, show a lower expression associated with in vitro
stress conditions [49,50]. For example, the induction
of ROS by mean of oxidant agents has been shown
to reduce the expression of a group of miRNAs,
including members of this cluster: miR-17, miR-18a,
miR-20a, miR-92a and the paralogs miR-106a and
miR-20b [14].
c. As shown by our results, miR-92 may also
participate in the complex interplay of factors up or
down-regulating apoptosis [51].
Conclusions
Our data indicate the existence of a link between oxida-
tive damage and miR-92 expression. In particular, this
study demonstrates, for the first time and in vivo, that
down-regulation of miR-92 significantly correlates with
both the extent of oxidative DNA damage and telomer-
ase activity in HCC. Additionally, miR-92 levels also cor-
related with Bad and Bax mRNA, involved in apoptotic
mechanisms.
Overall, our findings suggest that in chronic HCV-
related liver damage, the persistently increased ROS pro-
duction leads to accumulation of oxidative DNA dam-
age, which is only partially repaired by OGG1 in
association with other repair mechanisms. A deranged
expression of several miRNAs is confirmed, one of
which (miR-92) is apparently correlated with the extent
of oxidative stress and with telomerase activation in
HCC tissues.
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